Evidence map›Paper›PMID 36291596›Full record

ArticleBiomolecules2022

The Multicellular Effects of VDAC1 N-Terminal-Derived Peptide.

Uttpal Anand, Anna Shteinfer-Kuzmine, Gal Sela, Manikandan Santhanam, Benjamin Gottschalk, Rajaa Boujemaa-Paterski, Ohad Medalia, Wolfgang F Graier, Varda Shoshan-Barmatz

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Nano-biotechnology in tumour and cancerous disease: A perspective review.Journal of cellular and molecular medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Uttpal AnandDepartment of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.ORCID 0000-0001-5924-7866
Anna Shteinfer-KuzmineNational Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Gal SelaDepartment of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Manikandan SanthanamDepartment of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.ORCID 0000-0003-3798-9353
Benjamin GottschalkGottfried Schatz Research Center, Division of Molecular Biology and Biochemistry, Medical University of Graz, 8010 Graz, Austria.
Rajaa Boujemaa-PaterskiDepartment of Biochemistry, University of Zurich, 8057 Zurich, Switzerland.
Ohad MedaliaDepartment of Biochemistry, University of Zurich, 8057 Zurich, Switzerland.ORCID 0000-0003-0994-2937
Wolfgang F GraierGottfried Schatz Research Center, Division of Molecular Biology and Biochemistry, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0003-1871-3298
Varda Shoshan-BarmatzDepartment of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.ORCID 0000-0002-6756-4340
Ben-Gurion University of the Negev · ILMedical University of Graz · ATUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mitochondrial voltage-dependent anion channel-1 (VDAC1) protein functions in a variety of mitochondria-linked physiological and pathological processes, including metabolism and cell signaling, as well as in mitochondria-mediated apoptosis. VDAC1 interacts with about 150 proteins to regulate the integration of mitochondrial functions with other cellular activities. Recently, we developed VDAC1-based peptides that have multiple effects on cancer cells and tumors including apoptosis induction. Here, we designed several cell-penetrating VDAC1 N-terminal-derived peptides with the goal of identifying the shortest peptide with improved cellular stability and activity. We identified the D-Δ(1-18)N-Ter-Antp comprising the VDAC1 N-terminal region (19-26 amino acids) fused to the Antp, a cell-penetrating peptide. We demonstrated that this peptide induced apoptosis, autophagy, senescence, cell volume enlargement, and the refusion of divided daughter cells into a single cell, it was responsible for reorganization of actin and tubulin filaments, and increased cell adhesion. In addition, the peptide induced alterations in the expression of proteins associated with cell metabolism, signaling, and division, such as enhancing the expression of nuclear factor kappa B and decreasing the expression of the nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha. These cellular effects may result from the peptide interfering with VDAC1 interaction with its interacting proteins, thereby blocking multiple mitochondrial/VDAC1 pathways associated with cell functions. The results of this study further support the role of VDAC1 as a mitochondrial gatekeeper protein in controlling a variety of cell functions via interaction with associated proteins.

Indexed as

Cell-Penetrating PeptidesActinsAmino AcidsApoptosisNF-kappa BTubulinVoltage-Dependent Anion Channel 1ActinsAmino AcidsCell-Penetrating PeptidesNF-kappa BTubulinVoltage-Dependent Anion Channel 1apoptosismitochondriapeptide arrayprotein–protein interactionvoltage-dependent anion channel-1

Identifiers

PMID36291596
PMCPMC9599717
OpenAlexW4297464564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.